Get started
Eli Lilly & Co Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 ShEli Lilly & Co Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 ShEli Lilly & Co Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh

Eli Lilly & Co Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsSeasonalsBonds

Chart


Full chart

Key facts today


Eli Lilly (LLY) will launch its obesity drug Zepbound in January, priced at $299 monthly for the lowest dose. This follows Novo Nordisk's price cut for Wegovy, impacting LLY shares.
Eli Lilly reported above-average gross margins in its most recent fiscal year, outperforming many peers in the healthcare sector, which has faced various challenges this year.
Eli Lilly's tirzepatide, a GLP-1 weight-loss drug, showed temporary suppression of food cravings in a study. Effects lessened after five months, leading to a return of binge-eating.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪5.14 T‬ BRL
Dividend yield (indicated)
0.40%
Price to earnings Ratio (TTM)
3,164.05
Basic EPS (TTM)
0.06 BRL
Net income (FY)
‪57.09 B‬ BRL
Revenue (FY)
‪242.82 B‬ BRL
Shares float
—
Beta (1Y)
−0.38

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
ISIN
BRLILYBDR006
FIGI
BBG002QBHFC7
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LILY34.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043
Yield to maturity
5.73%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.65%
Maturity date
Jun 15, 2044
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
5.54%
Maturity date
Oct 15, 2065
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.53%
Maturity date
Feb 9, 2064
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065
Yield to maturity
5.52%
Maturity date
Feb 12, 2065
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059
Yield to maturity
5.50%
Maturity date
Mar 15, 2059
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.50%
Maturity date
Aug 14, 2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.49%
Maturity date
Feb 27, 2063
US532457BY3
Eli Lilly and Company 2.25% 15-MAY-2050
Yield to maturity
5.44%
Maturity date
May 15, 2050
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055
Yield to maturity
5.43%
Maturity date
Oct 15, 2055
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053
Yield to maturity
5.43%
Maturity date
Feb 27, 2053

See all LILY34 bonds 

Sparks


Curated watchlists where LILY34 is featured.

See all sparks